59
Views
0
CrossRef citations to date
0
Altmetric
Review

Individualized cardiac resynchronization therapy: current status

&
Pages 305-317 | Published online: 07 Nov 2014

References

  • McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–869.
  • Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137–1146.
  • Khan NK, Goode KM, Cleland JG, et al. Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. Eur J Heart Fail. 2007;9:491–501.
  • Clark AL, Goode K, Cleland JG. The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. Eur J Heart Fail. 2008;10:696–702.
  • Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.
  • Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549.
  • Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–1338.
  • Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–1853.
  • Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–2395.
  • Linde C, Abraham WT, Gold MR, Daubert C. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (resynchronization reverses remodeling in systolic left ventricular dysfunction) study. J Am Coll Cardiol. 2010;56:1826–1831.
  • Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281–2329.
  • Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61:e6–e75.
  • Wells G, Parkash R, Healey JS, et al. Cardiac resynchronization therapy: A meta-analysis of randomized controlled trials. CMAJ. 2011;183:421–429.
  • Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547–3556.
  • Bogale N, Priori S, Cleland JG, et al. The european CRT survey: 1 year (9–15 months) follow-up results. Eur J Heart Fail. 2012;14:61–73.
  • Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873–880.
  • Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39:2026–2033.
  • Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454–1459.
  • Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. 2003;289:2685–2694.
  • Abraham WT, Young JB, Leon AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864–2868.
  • Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834–1843.
  • Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370:1694–1701.
  • Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. Eur Heart J. 2013;34:2592–2599.
  • Exner DV, Birnie DH, Moe G, et al. Canadian cardiovascular society guidelines on the use of cardiac resynchronization therapy: evidence and patient selection. Can J Cardiol. 2013;29:182–195.
  • Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2012;9:1737–1753.
  • Thibault B, Harel F, Ducharme A, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: The evaluation of resynchronization therapy for heart failure (LESSER-EARTH) trial. Circulation. 2013;127:873–881.
  • Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). Circulation. 2011;123:1061–1072.
  • Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC. Impact of qrs duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med. 2011;171:1454–1462.
  • Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J. 2012;163:260–267.
  • Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in medicare patients. Circulation. 2010;122:2022–2030.
  • Peterson PN, Greiner MA, Qualls LG, et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. JAMA. 2013;310:617–626.
  • Miyazaki C, Powell BD, Bruce CJ, et al. Comparison of echocardiographic dyssynchrony assessment by tissue velocity and strain imaging in subjects with or without systolic dysfunction and with or without left bundle-branch block. Circulation. 2008;117:2617–2625.
  • Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608–2616.
  • Yu CM, Sanderson JE, Gorcsan J 3rd. Echocardiography, dyssynchrony, and the response to cardiac resynchronization therapy. Eur Heart J. 2010;31:2326–2337.
  • Risum N, Williams ES, Khouri MG, et al. Mechanical dyssynchrony evaluated by tissue doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy. Eur Heart J. 2013;34:48–56.
  • Bax JJ, Gorcsan J 3rd. Echocardiography and noninvasive imaging in cardiac resynchronization therapy: results of the PROSPECT (predictors of response to cardiac resynchronization therapy) study in perspective. J Am Coll Cardiol. 2009;53:1933–1943.
  • Bleeker GB, Holman ER, Steendijk P, et al. Cardiac resynchronization therapy in patients with a narrow qrs complex. J Am Coll Cardiol. 2006;48:2243–2250.
  • Yu CM, Chan YS, Zhang Q, et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. J Am Coll Cardiol. 2006;48:2251–2257.
  • Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007;357:2461–2471.
  • Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–1405.
  • Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2011;8:1088–1094.
  • Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J. 2002;23:1780–1787.
  • Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011;32:2420–2429.
  • Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005;16:1160–1165.
  • Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (cardiac resynchronization therapy in atrial fibrillation patients multinational registry). JACC Heart Fail. 2013;1:500–507.
  • Ruwald AC, Pietrasik G, Goldenberg I, et al. The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Am Coll Cardiol. 2014;63:1190–1197.
  • Stockburger M, Gomez-Doblas JJ, Lamas G, et al. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF). Eur J Heart Fail. 2011;13:633–641.
  • Yu CM, Chan JY, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med. 2009;361:2123–2134.
  • Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585–1593.
  • Funck RC, Blanc JJ, Mueller HH, et al. Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the ‘biventricular pacing for atrioventricular block to prevent cardiac desynchronization (BioPace)’ study. Europace. 2006;8:629–635.
  • Funck RC, Mueller HH, Lunati M, et al. Characteristics of a large sample of candidates for permanent ventricular pacing included in the biventricular pacing for atrio-ventricular block to prevent cardiac desynchronization study (BioPace). Europace. 2014;16:354–362.
  • Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation. 2011;123:1159–1166.
  • Thebault C, Donal E, Meunier C, et al. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the reverse trial. Eur Heart J. 2012;33:2662–2671.
  • Kutyifa V, Zareba W, McNitt S, et al. Left ventricular lead location and the risk of ventricular arrhythmias in the MADIT-CRT trial. Eur Heart J. 2013;34:184–190.
  • Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: The TARGET study: a randomized, controlled trial. J Am Coll Cardiol. 2012;59:1509–1518.
  • Saba S, Marek J, Schwartzman D, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the speckle tracking assisted resynchronization therapy for electrode region trial. Circ Heart Fail. 2013;6:427–434.
  • Sommer A, Kronborg MB, Poulsen SH, et al. Empiric versus imaging guided left ventricular lead placement in cardiac resynchronization therapy (ImagingCRT): study protocol for a randomized controlled trial. Trials. 2013;14:113.
  • Ge Y, Ruwald AC, Kutyifa V, et al. A metric for evaluating the cardiac response to resynchronization therapy. Am J Cardiol. 2014;113:1371–1377.
  • Becker M, Hoffmann R, Schmitz F, et al. Relation of optimal lead positioning as defined by three-dimensional echocardiography to long-term benefit of cardiac resynchronization. Am J Cardiol. 2007;100:1671–1676.
  • Bleeker GB, Kaandorp TA, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation. 2006;113:969–976.
  • Sade LE, Saba S, Marek JJ, et al. The association of left ventricular lead position related to regional scar by speckle-tracking echocardiography with clinical outcomes in patients receiving cardiac resynchronization therapy. J Am Soc Echocardiogr. 2014;27:648–656.
  • Delgado V, van Bommel RJ, Bertini M, et al. Relative merits of left ventricular dyssynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. Circulation. 2011;123:70–78.
  • Koplan BA, Kaplan AJ, Weiner S, et al. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009;53:355–360.
  • Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8:1469–1475.
  • Ruwald AC, Kutyifa V, Ruwald MH, et al. The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. Eur Heart J. Epub August 11, 2014. DOI: http://dx.doi.org/10.1093/eurheartj/ehu294.
  • Ruwald MH, Mittal S, Ruwald AC, et al. Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy. J Am Coll Cardiol. 2014;64:971–981.
  • Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010;122:2660–2668.
  • Martin DO, Lemke B, Birnie D, et al. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive crt trial. Heart Rhythm. 2012;9:1807–1814.
  • Naqvi TZ. Echocardiography-guided biventricular pacemaker optimization. JACC Cardiovasc Imaging. 2010;3:1168–1180.
  • Rafie R, Naqvi TZ. Echocardiography-guided biventricular pacemaker optimization: role of echo doppler in hemodynamic assessment and improvement. Expert Rev Cardiovasc Ther. 2012;10:859–874.
  • Gorcsan J 3rd, Abraham T, Agler DA, et al. Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy. J Am Soc Echocardiogr. 2008;21:191–213.
  • Raphael CE, Kyriacou A, Jones S, et al. Multinational evaluation of the interpretability of the iterative method of optimisation of av delay for crt. Int J Cardiol. 2013;168:407–413.
  • Risum N, Sogaard P, Hansen TF, et al. Comparison of dyssynchrony parameters for vv-optimization in crt patients. Pacing Clin Electrophysiol. 2013;36:1382–1390.
  • Leon AR, Abraham WT, Brozena S, et al. Cardiac resynchronization with sequential biventricular pacing for the treatment of moderate-to-severe heart failure. J Am Coll Cardiol. 2005;46:2298–2304.
  • Thomas DE, Yousef ZR, Fraser AG. A critical comparison of echocardiographic measurements used for optimizing cardiac resynchronization therapy: stroke distance is best. Eur J Heart Fail. 2009;11:779–788.
  • Mortensen PT, Sogaard P, Mansour H, et al. Sequential biventricular pacing: evaluation of safety and efficacy. Pacing Clin Electrophysiol. 2004;27:339–345.
  • Boriani G, Muller CP, Seidl KH, et al. Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. The resynchronization for the hemodynamic treatment for heart failure management ii implantable cardioverter defibrillator (RHYTHM II ICD) study. Am Heart J. 2006;151:1050–1058.
  • Rao RK, Kumar UN, Schafer J, et al. Reduced ventricular volumes and improved systolic function with cardiac resynchronization therapy: a randomized trial comparing simultaneous biventricular pacing, sequential biventricular pacing, and left ventricular pacing. Circulation. 2007;115:2136–2144.
  • Gras D, Gupta MS, Boulogne E, Guzzo L, Abraham WT. Optimization of AV and VV delays in the real-world CRT patient population: an international survey on current clinical practice. Pacing Clin Electrophysiol. 2009;32 Suppl 1:S236–S239.
  • Whinnett ZI, Sohaib SM, Jones S, et al. British randomised controlled trial of AV and VV optimization (“BRAVO”) study: rationale, design, and endpoints. BMC Cardiovasc Disord. 2014;14:42.
  • Schmidt S, Hurlimann D, Starck CT, et al. Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. Eur Heart J. 2014;35:1051–1060.
  • Fung JW, Chan JY, Kum LC, et al. Suboptimal medical therapy in patients with systolic heart failure is associated with less improvement by cardiac resynchronization therapy. Int J Cardiol. 2007;115:214–219.
  • Penn J, Goldenberg I, McNitt S, et al. Changes in drug utilization and outcome in relation to the efficacy of cardiac resynchronization in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT). J Am Coll Cardiol. 2014;63:12S.
  • Heywood JT, Fonarow GC, Yancy CW, et al. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail. 2010;3:596–605.
  • Voigt A, Shalaby A, Adelstein E, Saba S. Beta-blocker utilization and outcomes in patients receiving cardiac resynchronization therapy. Clin Cardiol. 2010;33:E1–E5.
  • Ruwald MH, Ruwald AC, Jons C, et al. Effect of metoprolol versus carvedilol on outcomes in madit-crt (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Am Coll Cardiol. 2013;61:1518–1526.
  • Ruwald MH, Abu-Zeitone A, Jons C, et al. Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (multicenter automatic defibrillator implantation with cardiac resynchronization therapy). J Am Coll Cardiol. 2013;62:1343–1350.
  • Mullens W, Grimm RA, Verga T, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53:765–773.
  • Mullens W, Kepa J, De Vusser P, et al. Importance of adjunctive heart failure optimization immediately after implantation to improve long-term outcomes with cardiac resynchronization therapy. Am J Cardiol. 2011;108:409–415.
  • Altman RK, Parks KA, Schlett CL, et al. Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes. Eur Heart J. 2012;33:2181–2188.
  • Alaeddini J, Wood MA, Amin MS, Ellenbogen KA. Gender disparity in the use of cardiac resynchronization therapy in the united states. Pacing Clin Electrophysiol. 2008;31:468–472.
  • Ector H, Vardas P. Current use of pacemakers, implantable cardioverter defibrillators, and resynchronization devices: data from the registry of the European Heart Rhythm Association. 2007;9:I44–I49.
  • Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28:42–51.
  • Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ. 2007;335:925.
  • Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy). J Am Coll Cardiol. 2011;57:2416–2423.
  • Ruwald MH, Solomon SD, Foster E, et al. Left Ventricular Ejection Fraction Normalization in Cardiac Resynchronization Therapy and Risk of Ventricular Arrhythmias and Clinical Outcomes: Results from the MADIT-CRT Trial. Circulation. Epub 2014 Oct 9.
  • Barsheshet A, Moss AJ, Huang DT, et al. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 2012;59:2075–2079.
  • Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
  • Goldenberg I, Moss AJ, Hall WJ, et al. Predictors of response to cardiac resynchronization therapy in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT). Circulation. 2011;124:1527–1536.
  • Danish Study Group. Danish ICD study in patients With dilated cardiomyopathy (DANISH). NLM identifier: NCT00542945.
  • Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med. 2011;154:401–412.
  • Adabag S, Roukoz H, Anand IS, Moss AJ. Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:935–941.
  • Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9:728–735.
  • Kirkfeldt RE, Johansen JB, Nohr EA, et al. Risk factors for lead complications in cardiac pacing: a population-based cohort study of 28,860 Danish patients. Heart Rhythm. 2011;8:1622–1628.
  • Kirkfeldt RE, Johansen JB, Nohr EA, et al. Pneumothorax in cardiac pacing: a population-based cohort study of 28,860 Danish patients. Europace. 2012;14:1132–1138.
  • Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35:1186–1194.